Immatics NV (IMTX) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $10.13
• Market Cap: $1.38B
• EPS: $-1.10
• 52-Week High: $12.41
• 52-Week Low: $3.30

Market Sentiment

Immatics NV currently has a Bullish sentiment score of 0.23.

About Immatics NV

Immatics NV is a pioneering clinical-stage biopharmaceutical firm based in Tübingen, Germany, focused on advancing T-cell receptor (TCR) based immunotherapies for cancer treatment. Harnessing its proprietary platform, the company identifies and targets unique cancer-specific antigens, which may significantly improve immune responses against tumors. With a robust pipeline of innovative therapeutics, Immatics is strategically positioned to meet critical unmet needs in oncology, representing a c...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Immatics NV and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does IMTX pay dividends?

Immatics NV (IMTX) does not currently pay a regular dividend.

What is IMTX's market cap?

Immatics NV (IMTX) has a market capitalization of $1.38B with a current stock price of $10.13.